WALTHAM, Mass., May 10, 2017 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney and vascular diseases, today announced financial results for the quarter ended March 31, 2017, and recent business highlights.
“Proteon continues to make significant clinical progress evaluating vonapanitase for patients with chronic kidney disease and peripheral artery disease,” said Timothy Noyes, President and Chief Executive Officer of Proteon. “We are greatly encouraged by the FDA’s recent decision to award vonapanitase Breakthrough Therapy designation and we remain on track to complete enrollment in our Phase 3 PATENCY-2 trial in the first quarter of 2018. Additionally, we are on track to enroll 24 patients in our Phase 1 clinical trial in patients with peripheral artery disease by the end of the year.”
